The panelists believe healthcare reform transparency has caused a significant reduction in pricing variability, and this has prompted many providers to try to renegotiate rates. Such transparency is also pushing providers to make their pricing information more freely accessible on-line, yet there is some concern that antitrust laws are being used to squash this nascent movement.
Healthcare pricing variability is decreasing tremendously, according to Francois de Brantes, MS, MBA, executive director, Health Care Incentives Improvement Institute, Newtown, Connecticut. Mr. de Brantes describes a report from the state of New Hampshire, the first state to regulate pricing transparency. The report indicates “There has been no effect in prices going up as a result of the transparency.”
This transparency and increased availability of pricing information is causing even the most expensive providers to try to find ways to renegotiate rates to keep their members. Blue Cross and Blue Shield of North Carolina has what Mr de Brantes considers “the most aggressive and well-done transparency tool on pricing.” In fact, “you don’t have to be a plan member… that information is freely accessible on the Web, and they show full episode costs for a number of things [and] the comparisons between the hospitals.”
Arthur Vercillo, MD, FACS, a surgeon and regional president of Excellus Blue Cross Blue Shield, acknowledges that higher-paid providers are worried about the current move toward transparency, “and that’s a good thing.” Dr Vercillo believes products are now being developed with pricing transparency in mind. He explains that nobody wants to be the one charging too little, nor the one charging too much.
Mr de Brantes believes there is no legitimacy to antitrust concerns related to price transparency. “All the arguments that have been put forth are bogus,” he insists, “because if they truly did violate a federal statute . . . or they violated consumer rights, the lawsuits would have gone up to the Supreme Court by now, and they haven’t.” Mr de Brantes adds, “There’s absolutely no legal standing for these arguments.” Dr Vercillo acknowledges the antitrust issue, but believes the benefits of transparency outweigh his concerns, and he is willing to “take the risk of the leverage that could be exerted because the benefit is that big, that important.”
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At The Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Commonwealth Fund Report Details Pervasive Racial and Ethnic Disparities in US Health Care, Outcomes
April 18th 2024Using 25 health system performance indicators, the Commonwealth Fund 2024 State Health Disparities Report evaluated racial and ethnic disparities in health care and health outcomes both within and across US states and highlighted the urgent need for equitable health care policies and practices in the US.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Study Links COVID-19 Pandemic to Rise in Neoadjuvant Chemotherapy for Ovarian Cancer in US
April 17th 2024There was greater use of neoadjuvant chemotherapy among US patients with ovarian cancer (OC) during the COVID-19 pandemic to reduce potential COVID-19 exposure and cancer treatment-related complications.
Read More
Beyond Insulin: The Impact of Next-Generation Diabetes Technology
April 17th 2024Experts explain how new diabetes technologies like continuous glucose monitors are transforming care beyond intensive insulin therapy, offering personalized insights and improving outcomes for patients of all treatment levels.
Read More